Dilek ÜNAL, İpek MÜDERRİS, Başak CINĞILLIOĞLU, Hüseyin AKSOY, Ülkü AKSOY, Sezin ÖZYURT, Gülender TEKİN TAŞ, Gökhan AÇMAZ

Anormal Uterin Kanamalı Hastalarda Nötrofil/Lenfosit Oranı ve Platelet/Lenfosit Oranı Endometrial Hiperplazi ve Progestoron Tedavisi ile İlişkili midir?

Aim: An easy, reproducible, non-invasive and simple marker is needed to distinguish endometrial hyperplasia andnormal pathologic results. We aimed to clarify association among neutrophil-to-lymphocyte ratio (NLR), plateletto-lymphocyte ratio (PLR), endometrial hyperplasia and normal pathologic results in patients with abnormal uterinebleeding. Material and Methods: Patients (n=80) who were administered with abnormal uterine bleeding and the presence ofendometrial cells on cervical cytology or thick endometrium were investigated. The study constituted of two groupsaccording to pathologic diagnosis of volunteers. Hyperplasia group included endometrial precancerous lesions likesimple hyperplasia without atipia (n=40), normal pathology group included patients who had normal pathologicresults (n=40). Additionally we divided endometrial hyperplasia patients into two groups according to progesteronetreatment response. Group 1 (women who treated with progesterone and second curettage result was defined as be- nign lesions group n=32), group 2 (women who treated with progesterone and second curettage result was definedas precancerous lesion EH n=8) then subgroup comparisons were made between two groups. Blood samples wereobtained just before curettage procedure and the NLR was defined as the absolute neutrophil count divided by theabsolute lymphocyte count; similarly, PLR was defined as the absolute platelet count divided by the absolute lym- phocyte count. Results: Mean age was 46.1 ± 6.1 years in hyperplasia group and 45.6±4.0 years in control group. Median neutrophilto lymphocyte ratio and platelet to lymphocyte ratio were 2.01 (0.95-5.75) and 1.81 (0.94 4.01), 147 ± 59 and 128± 48 respectively. There were no significant differences between groups for hemoglobin, hematocrit, anemia, WBC,NLR, PLR and platelet values. Additionally these parameters did not differ after three months progesterone treatment. Conclusions: As far as we know, there have been no previous studies that have investigated these parameters forevaluating progesterone treatment response in patients with hyperplasia and distinguishing endometrial hyperplasiaand pathologically normal patients. We did not find any significant differences between both groups. By using mul- tiple inflammation parameters, discrimination may not be possible between endometrial precancerous lesions andpathologically normal patients.

Are Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios Associated With Endometrial Hyperplasia and Progesterone Treatment in Patients With Abnormal Uterine Bleeding?

Aim: An easy, reproducible, non-invasive and simple marker is needed to distinguish endometrial hyperplasia andnormal pathologic results. We aimed to clarify association among neutrophil-to-lymphocyte ratio (NLR), platelet- to-lymphocyte ratio (PLR), endometrial hyperplasia and normal pathologic results in patients with abnormal uterinebleeding. Material and Methods: Patients (n=80) who were administered with abnormal uterine bleeding and the presence ofendometrial cells on cervical cytology or thick endometrium were investigated. The study constituted of two groupsaccording to pathologic diagnosis of volunteers. Hyperplasia group included endometrial precancerous lesions likesimple hyperplasia without atipia (n=40), normal pathology group included patients who had normal pathologicresults (n=40). Additionally we divided endometrial hyperplasia patients into two groups according to progesteronetreatment response. Group 1 (women who treated with progesterone and second curettage result was defined as be- nign lesions group n=32), group 2 (women who treated with progesterone and second curettage result was definedas precancerous lesion EH n=8) then subgroup comparisons were made between two groups. Blood samples wereobtained just before curettage procedure and the NLR was defined as the absolute neutrophil count divided by theabsolute lymphocyte count; similarly, PLR was defined as the absolute platelet count divided by the absolute lym- phocyte count. Results: Mean age was 46.1 ± 6.1 years in hyperplasia group and 45.6±4.0 years in control group. Median neutrophilto lymphocyte ratio and platelet to lymphocyte ratio were 2.01 (0.95-5.75) and 1.81 (0.94 4.01), 147 ± 59 and 128± 48 respectively. There were no significant differences between groups for hemoglobin, hematocrit, anemia, WBC,NLR, PLR and platelet values. Additionally these parameters did not differ after three months progesterone treatment. Conclusions: As far as we know, there have been no previous studies that have investigated these parameters forevaluating progesterone treatment response in patients with hyperplasia and distinguishing endometrial hyperplasiaand pathologically normal patients. We did not find any significant differences between both groups. By using mul- tiple inflammation parameters, discrimination may not be possible between endometrial precancerous lesions and pathologically normal patients.

PDF

___

1. Turan T, Karadag B, Karabuk E et al. Accuracy of Frozen Sections for Intraoperative Diagnosis of Complex Atypical Endometrial Hyperplasia. Asian Pacific J Cancer Prev 2012;13:1953-1956 .
2. Heller DS, Mosquera C, Goldsmith LT, Cracchiolo B. Body mass index of patients with endometrial hyperplasia: comparison to patients with proliferative endometrium and abnormal bleeding. J Reprod Med. 2011; 56(3-4):110-112.
3. Ricciardi E, Maniglio P, Frega A, Marci R, Caserta D, Moscarini M. Fertility-sparing treatment of endometrial cancer precursors among young women: a reproductive point of view. Eur Rev Med Pharmacol Sci 2012 Dec;16(14):1934-1937.
4. Babu SN, Chetal G, Kumar S. Macrophage migration inhibitory factor: a potential marker for cancer diagnosis and therapy. Asian Pac J Cancer Prev 2012; 13:1737-1744.
5. Yong-Zhong Guo, Lei Pan, Chang-Jun Du, Dun-Qiang Ren, Xiao- Mei Xie. Association Between C-reactive Protein and Risk of Cancer: A Meta-analysis of Prospective Cohort Studies. Asian Pacific J Cancer Prev 2013; 14: 243-248.
6. Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to- lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010; 16:5805-5013.
7. Sharaiha RZ, Halazun KJ, Mirza F, et al. Elevated preoperative neutrophil: lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol 2011; 18:3362-3369.
8. Kwon HC, Kim SH, Oh SY, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012; 17:216-322.
9. Kleebkaow P, Maneetab S, Somboonporn W, et al. Preoperative and Postoperative Agreement of Histopathological Findings in Cases of Endometrial Hyperplasia. Asian Pac J Cancer Prev 2008; 9:89-91.
10. Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol. 2005; 97:924.
11. Casper RF. Regulation of estrogen/progestogen receptors in the endometrium. Int J Fertil Menopausal Stud 1996; 41:16.
12. Tavares-Murta BM, Mendonça MA, Duarte NL, et al. Systemic leukocyte alterations are associated with invasive uterine cervical cancer. Int J Gynecol Cancer 2010; 20:1154-1159. 13. Choi CH, Kang H, Kim WY, et al. Prognostic value of baseline lymphocyte count in cervical carcinoma treated with concurrent chemoradiation. Int J Radiat Oncol Biol Phys 2008; 71: 199-204.
14. Choi CH, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS. Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma. Gynecol Oncol 2006; 104: 64-69.
15. Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A. Are Neutrophil/ Lymphocyte and Platelet/Lymphocyte Rates in Patients with Non- Small Cell Lung Cancer Associated with Treatment Response and Prognosis? Asian Pac J Cancer Prev 2013; 14: 5237-5242.
16. Négrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d Immunotherapie. Ann Oncol 2002; 13:1460-1468.
17. Teramukai S, Kitano T, Kishida Y, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non- small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 2009; 45:1950-1958.
18. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGFβ: N1 versus N2 TAN. Cancer Cell 2009; 16:183-194.